Cargando…

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition

It has been uncertain whether specific disease-relevant biomarker phenotypes can be found using sporadic Parkinson’s disease (PD) patient-derived samples, as it has been proposed that there may be a plethora of underlying causes and pathological mechanisms. Fibroblasts derived from familial PD patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, G. A., Jansson, J., Rocha, E. M., Osborn, T., Hallett, P. J., Isacson, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012155/ https://www.ncbi.nlm.nih.gov/pubmed/26399642 http://dx.doi.org/10.1007/s12035-015-9435-4

Ejemplares similares

Regulators of proteostasis are translationally repressed in fibroblasts from patients with sporadic and LRRK2-G2019S Parkinson’s disease
por: Flinkman, Dani, et al.
Publicado: (2023)

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
por: Korecka, Joanna A., et al.
Publicado: (2020)

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
por: Gonzalez-Hunt, C. P., et al.
Publicado: (2020)

Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids
por: Kim, Hongwon, et al.
Publicado: (2019)

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
por: Aasly, Jan O., et al.
Publicado: (2015)

Analysis of Nigerians with Apparently Sporadic Parkinson Disease for Mutations in LRRK2, PRKN and ATXN3
por: Okubadejo, Njideka, et al.
Publicado: (2008)

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
por: Rudenko, Iakov N, et al.
Publicado: (2012)

LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease
por: Rocha, Emily M., et al.
Publicado: (2019)

Advantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients
por: Osborn, Teresia M., et al.
Publicado: (2020)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinson’s Disease: A Pilot Study
por: Yilmaz, Ali, et al.
Publicado: (2020)

Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson’s disease
por: Cording, Amy C., et al.
Publicado: (2017)

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
por: Deng, Xianming, et al.
Publicado: (2011)

Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
por: Purlyte, Elena, et al.
Publicado: (2017)

Neurite Collapse and Altered ER Ca(2+) Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation
por: Korecka, Joanna A., et al.
Publicado: (2018)

A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
por: Vissers, Maurits F. J. M., et al.
Publicado: (2023)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

Analysis of LRRK2, SNCA, and ITGA8 Gene Variants with Sporadic Parkinson's Disease Susceptibility in Chinese Han Population
por: Fang, Jie, et al.
Publicado: (2016)

Differences in MTHFR and LRRK2 variant’s association with sporadic Parkinson’s disease in Mexican Mestizos correlated to Native American ancestry
por: Romero-Gutiérrez, Elizabeth, et al.
Publicado: (2021)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
por: Bright, Jessica M., et al.
Publicado: (2021)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
por: De Wit, T., et al.
Publicado: (2018)

Exosome markers of LRRK2 kinase inhibition
por: Wang, Shijie, et al.
Publicado: (2020)

LRRK2 Kinase Inhibition Attenuates Neuroinflammation and Cytotoxicity in Animal Models of Alzheimer’s and Parkinson’s Disease-Related Neuroinflammation
por: Mutti, Veronica, et al.
Publicado: (2023)

Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures
por: Sanz Murillo, Marta, et al.
Publicado: (2023)

Antioxidants inhibit neuronal toxicity in Parkinson's disease‐linked LRRK2
por: Angeles, Dario C., et al.
Publicado: (2016)

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease
por: Rideout, Hardy J., et al.
Publicado: (2020)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

LRRK2 in Parkinson's disease and dementia with Lewy bodies
por: Zhu, Xiongwei, et al.
Publicado: (2006)

Progressive decline of glucocerebrosidase in aging and Parkinson's disease
por: Rocha, Emily M, et al.
Publicado: (2015)

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
por: Steger, Martin, et al.
Publicado: (2016)

Inhibition of LRRK2 kinase activity stimulates macroautophagy()
por: Manzoni, Claudia, et al.
Publicado: (2013)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kbm9ba4kq5h4ot11r9ctes0he3